Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
- 28 April 2005
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 19 (7) , 1207-1210
- https://doi.org/10.1038/sj.leu.2403782
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Campath-1H monoclonal antibody therapyCurrent Opinion in Oncology, 2000
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complementBlood, 1983